BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esfahani MKM, Islam N, Cabot PJ, Izake EL. Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy. ACS Biomater Sci Eng 2021. [PMID: 34056895 DOI: 10.1021/acsbiomaterials.1c00066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Shah S, Famta P, Bagasariya D, Charankumar K, Sikder A, Kashikar R, Kotha AK, Chougule MB, Khatri DK, Asthana A, Raghuvanshi RS, Singh SB, Srivastava S. Tuning Mesoporous Silica Nanoparticles in Novel Avenues of Cancer Therapy. Mol Pharm 2022;19:4428-52. [PMID: 36109099 DOI: 10.1021/acs.molpharmaceut.2c00374] [Reference Citation Analysis]
2 Alavi SE, Raza A, Gholami M, Giles M, Al-sammak R, Ibrahim A, Ebrahimi Shahmabadi H, Sharma LA. Advanced Drug Delivery Platforms for the Treatment of Oral Pathogens. Pharmaceutics 2022;14:2293. [DOI: 10.3390/pharmaceutics14112293] [Reference Citation Analysis]
3 Kumeria T. Advances on Porous Nanomaterials for Biomedical Application (Drug Delivery, Sensing, and Tissue Engineering). ACS Biomater Sci Eng 2022;8:4025-7. [PMID: 36210773 DOI: 10.1021/acsbiomaterials.2c01103] [Reference Citation Analysis]
4 Johnson RP, Ratnacaram CK, Kumar L, Jose J. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer. Drug Resist Updat 2022;64:100865. [PMID: 36099796 DOI: 10.1016/j.drup.2022.100865] [Reference Citation Analysis]
5 Khursheed R, Dua K, Vishwas S, Gulati M, Jha NK, Aldhafeeri GM, Alanazi FG, Goh BH, Gupta G, Paudel KR, Hansbro PM, Chellappan DK, Singh SK. Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives. Biomed Pharmacother 2022;150:112951. [PMID: 35447546 DOI: 10.1016/j.biopha.2022.112951] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
6 Koohi Moftakhari Esfahani M, Alavi SE, Cabot PJ, Islam N, Izake EL. β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells. Pharmaceutics 2022;14:884. [PMID: 35456716 DOI: 10.3390/pharmaceutics14040884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Ghaferi M, Zahra W, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: an in vitro study. EXCLI J 2022;21:236-49. [PMID: 35221842 DOI: 10.17179/excli2021-4491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Sulaiman S, Ahmad S, Naz SS, Qaisar S, Muhammad S, Alotaibi A, Ullah R. Synthesis of Copper Oxide-Based Nanoformulations of Etoricoxib and Montelukast and Their Evaluation through Analgesic, Anti-Inflammatory, Anti-Pyretic, and Acute Toxicity Activities. Molecules 2022;27:1433. [PMID: 35209221 DOI: 10.3390/molecules27041433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mondal A, Paul P, Banerjee S. Applications of metal oxide nanoparticles in cancer therapy. Advances in Nanotechnology-Based Drug Delivery Systems 2022. [DOI: 10.1016/b978-0-323-88450-1.00013-2] [Reference Citation Analysis]
10 Hajnal K, Edina MP, Adrienn R, Lajos-attila P. Chemical and pharmacological characterization of anthelmintic benzimidazoles. Bulletin of Medical Sciences 2021;94:88-96. [DOI: 10.2478/orvtudert-2021-0013] [Reference Citation Analysis]
11 Hu Y, Bai S, Wu X, Tan S, He Y. Biodegradability of mesoporous silica nanoparticles. Ceramics International 2021;47:31031-41. [DOI: 10.1016/j.ceramint.2021.08.129] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Esfahani MKM, Alavi SE, Cabot PJ, Islam N, Izake EL. PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics 2021;13:1605. [PMID: 34683898 DOI: 10.3390/pharmaceutics13101605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]